Mobile

A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthrit...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000482-35

A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the anti-inflammatory efficacy of rosiglitazone XR 8 mg administered once daily for a period of 6 months to subjects with rheumatoid arthritis who demonstrate active disease despite disease-modifying antirheumatic drug (DMARD) therapy.

Critère d'inclusion

  • Rheumatoid Arthritis

Liens